Stenocare A/S (XSAT:STENO) Debt-to-Equity : 0.38 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Stenocare A/S Debt-to-Equity?

Stenocare A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr8.75 Mil. Stenocare A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.94 Mil. Stenocare A/S's Total Stockholders Equity for the quarter that ended in Dec. 2023 was kr25.82 Mil. Stenocare A/S's debt to equity for the quarter that ended in Dec. 2023 was 0.37.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Stenocare A/S's Debt-to-Equity or its related term are showing as below:

XSAT:STENO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.38 Max: 0.45
Current: 0.38

During the past 6 years, the highest Debt-to-Equity Ratio of Stenocare A/S was 0.45. The lowest was 0.03. And the median was 0.38.

XSAT:STENO's Debt-to-Equity is ranked worse than
57.71% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs XSAT:STENO: 0.38

Stenocare A/S Debt-to-Equity Historical Data

The historical data trend for Stenocare A/S's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stenocare A/S Debt-to-Equity Chart

Stenocare A/S Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.45

0.38

Stenocare A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.45	0.57	0.30	0.35	0.38

Competitive Comparison of Stenocare A/S's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Stenocare A/S's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stenocare A/S's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Stenocare A/S's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Stenocare A/S's Debt-to-Equity falls into.

Stenocare A/S Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Stenocare A/S's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.746	+	0.936)	/	25.822
	=	0.37

Stenocare A/S's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.746	+	0.936)	/	25.822
	=	0.37

Stenocare A/S (XSAT:STENO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Stenocare A/S Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Stenocare A/S's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Stenocare A/S (XSAT:STENO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Stenocare A/S (XSAT:STENO) » Definitions » Debt-to-Equity

Traded in Other Exchanges

STENO:Denmark S7C:Germany

Address

Nyholmsvej 4, Randers NØ, DNK, 8930

Website

https://www.stenocare.com

Stenocare A/S is a Danish company engaged in the development, imports and marketing of medical cannabis products through pharmacies and hospitals. The Company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The Company is a supplier of medical cannabis oil for patients in Denmark, Sweden, UK, Australia and Norway. It has an indoor production facility for the cultivation and production of medical cannabis at Randers, Denmark. The company's product offering includes medical cannabis oil like CBD DROPS STENOCARE, 1: 1 DROPS STENOCARE, and THC DROPS STENOCARE.

Stenocare A/S (XSAT:STENO) Headlines

No Headlines